

Welichem Files its Annual Audited Financials for Year Ended May 31, 2008, and Announces its AGM/SGM Date

VANCOUVER, Sept. 26 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that the Company filed its annual audited financials and MD & A. The net loss for the three-month period ended May 31, 2008, was \$817,695 (2007 - \$689,791), or 1 cent per share (2007 - 1 cent per share). The net loss for the 1-year period ended May 31, 2008, was \$2,519,988 (2007 - \$3,201,151), or 3 cents per share (2007 - 5 cents per share). Detailed information is available on the SEDAR and Welichem websites (www.sedar.com and www.welichem.com).

The Company also announced that its Annual and Special General Meeting will be held at The Simon Fraser University, Segal Centre, Room 1400-1410, 515 West Hastings Street, Vancouver, British Columbia (SFU Downtown Campus), at 1:00 p.m., Pacific Daylight Time, on Monday, October 28, 2008. Detailed information is also available on the SEDAR and Welichem websites (www.sedar.com and www.welichem.com).

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune, inflammatory diseases and cancer.

ON BEHALF OF THE BOARD
Genhui Chen, Ph.D.
President & Chief Executive Officer

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements. The Company thus seeks safe harbour

For further information

Dr. Genhui Chen, Tel.: (604) 432-1703, Email: gchen@welichem.com